Heparin mimetics

Handbook of Experimental Pharmacology

Volumn 207, Issue , 2012, Pages 361-383

  Coombe, Deirdre R ^a   Kett, Warren C ^b  

^a CURTIN UNIVERSITY   (Australia)

^b Glycan Biosciences Inc   (United States)

Author keywords

Glycosaminoglycan; GMI 1070; Heparin; Heparin mimetics; PI 88; RGTAs

Indexed keywords

ALGINIC ACID; APROSULATE; CACIPLIQ20; CD31 ANTIGEN; CELLULOSE; CELLULOSE SULFATE; CHITIN; DEXTRAN; EP 217609; FONDAPARINUX; GALACTAN; GMI 1070; HEPARIN; HEPARIN DERIVATIVE; HEPARIN MIMETIC; HIRUDOID; INULIN; OTR 4120; PEGAPTANIB; PENTOSAN POLYSULFATE; PI 88; PRO 2000; RG 1192; RG 1503; RGTA 11; SUCRALFATE; SUCROSOFATE; SURAMIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIVAGEL;

ANTICOAGULATION; ARTICLE; ASTHMA; BLEEDING; BURN; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERSTITIAL CYSTITIS; INTESTINAL BLEEDING; LIVER CANCER; LIVER TOXICITY; METASTATIC MELANOMA; MOLECULAR WEIGHT; PRION DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN METHYLATION; RECOMMENDED DRUG DOSE; RECTUM HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; STEREOCHEMISTRY; THROMBOSIS; UNSPECIFIED SIDE EFFECT; URTICARIA; WOUND HEALING; CHEMICAL STRUCTURE; CHEMISTRY; MOLECULAR MIMICRY; REVIEW;

HEPARIN; MOLECULAR MIMICRY; MOLECULAR STRUCTURE;

EID: 84861898052     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-23056-1_16     Document Type: Article

References (110)

1. Adamiak B, Ekblad M, Bergstr€om T, Ferro V, Trybala E (2007) Herpes simplex virus type 2 glycoprotein G is targeted by the sulfated oligo- and polysaccharide inhibitors of virus attachment to cells. J Virol 81:13424-13434
2. Adams Y, Freeman C, Schwartz-Albiez R, Ferro V, Parish CR, Andrews KT (2006) Inhibition of Plasmodium falciparum growth in vitro and adhesion to chondroitin-4-sulfate by the heparan sulfate mimetic PI-88 and other sulfated oligosaccharides . Antimicrob Agents Chemother 50:2850-2852
3. Alban S (2011) Adverse effects of heparin. In: Lever R, Mulloy B, Page CP (eds) Heparin - a century of progress. Springer, Heidelberg
4. Alexakis C, Mestries P, Garcia S, Petit E, Barbier V, Papy-Garcia D, Sagot M-A, Barritault D, Caruelle JP, Kern P (2004) Structurally different RGTAs modulate collagen-type expression by cultured aortic smooth muscle cells via different pathways involving fibroblast growth factor-2 or transforming growth factor-b1 . FASEB J 18:1147-1159
5. Barritault D, Caruelle J-P (2004) Biocompatible polymers, process for their preparation and compositions containing them, Patent No. US 6689741
6. Barritault DP, Caruelle J-P (2009) Biocompatible polymers, process for their preparation and compositions containing them, Patent No. US 2009/0012040 A1
7. Basten JE, Dreef-Tromp CM, de Wijs B, van Boeckel CA (1998) In vitro evaluation of synthetic heparin-like conjugates comprising different thrombin binding domains. Bioorg Med Chem Lett 8:1201-1206
8. Baumann H, Richter A, Klemm D, Faust V (2000) Concepts for preparation of novel regioselective modified cellulose derivatives sulfated, aminated, carboxylated and acetylated for hemocompatible ultrathin coatings on biomaterials. Macromol Chem Phys 201:1950-1962
9. van Boeckel CAA, Petitou M (1993) The unique antithrombin III binding domain of heparin: A lead to new synthetic antithrombotics. Angew Chem Int Ed Engl 32:1671-1690
10. Bugatti A, Urbinati C, Ravelli C, De Clercq E, Liekens S, Rusnati M (2007) Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 Tat and gp120 proteins. Antimicrob Agents Chemother 51:2337-2345
11. Buijsman RC, Basten JE, Dreef-Tromp CM, van der Marel GA, van Boeckel CA, van Boom JH (1999) Synthesis of heparin-like antithrombotics having perphosphorylated thrombin binding domains. Bioorg Med Chem 7:1881-1890
12. Burgermeister J, Paper DH, Vogl H, Linhardt RJ, Franz G (2002) LaPSvS1, a (1- > 3)-betagalactan sulfate and its effect on angiogenesis in vivo and in vitro. Carbohydr Res 337: 1459-1466
13. Casu B, Guerrini M, Guglieri S, Naggi A, Perez M, Torri G, Cassinelli G, Ribatti D, Carminati P, Giannini G, Penco S, Pisano C, Belleri M, Rusnati M, Presta M (2004) Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Med Chem 47:838-848
14. Casu B, Naggi A, Torri G (2001) Glycosaminoglycans having high antithrombotic activity, Patent No. US 6197943
15. Casu B, Vlodavsky I, Sanderson RD (2008) Non-anticoagulant heparins and inhibition of cancer . Pathophysiol Haemost Thromb 36:195-203
16. Casu BM, Torri GM, Naggi AMM, Giannini GP, Pisano CP, Penco SM (2005) Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect, Patent No. US 2005/0222084 A1
17. Chaikof EL, Grande D, Baskaran S (2007) Glycopolymers and free radical polymerization methods, Patent No. US 7244830
18. Charef S, Petit E, Barritault D, Courty J, Caruelle JP (2007) Effects on coagulation of a synthetic heparin mimetic given intraperitoneally or orally. J Biomed Mater Res 83A:1024-1031
19. Chow LQM, Gustafson DL, O'Bryant CL, Gore L, Basche M, Holden SN, Morrow MC, Grolnic S, Creese BR, Roberts KL, Davis K, Addison R, Eckhardt SG (2008) A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies . Cancer Chemother Pharmacol 63:65-74
20. Christensen ND, Reed CA, Culp TD, Hermonat PL, Howett MK, Anderson RA, Zaneveld LJ (2001) Papillomavirus microbicidal activities of high-molecular-weight cellulose sulfate, dextran sulfate, and polystyrene sulfonate. Antimicrob Agents Chemother 45:3427-3432
21. Chucholowski A, Fingerle J, Iberg N, Marki HP, Muller R, Pech M, Rouge M, Schmid G, Tschopp T, Wessel HP (1996) Sulfuric acid esters of sugar alcohols, Patent No. US5521160
22. Cipriani TR, Gracher AH, de Souza LM, Fonseca RJ, Belmiro CL, Gorin PA, Sassaki GL, Iacomini M (2009) Influence of molecular weight of chemically sulfated citrus pectin fractions on their antithrombotic and bleeding effects. Thromb Haemost 101:860-866
23. Cochran S, Li C, Fairweather JK, Kett WC, Coombe DR, Ferro V (2003) Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance. J Med Chem 46:4601-4608
24. Crandall IE, Szarek WA, Vlahakis JZ, Xu Y, Vohra R, Sui J, Kisilevsky R (2007) Sulfated cyclodextrins inhibit the entry of Plasmodium into red blood cells. Implications for malarial therapy. Biochem Pharmacol 73:632-642
25. De Clercq E (2009a) Antiviral drug discovery: ten more compounds, and ten more stories (part B). Med Res Rev 29:571-610
26. De Clercq E (2009b) The next ten stories on antiviral drug discovery (part E): Advents, advances, and adventures. Med Res Rev. doi:10.1002/med.20179
27. Demir M, Iqbal O, Hoppensteadt DA, Piccolo P, Ahmad S, Schultz CL, Linhardt RJ, Fareed J (2001) Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88). Clin Appl Thromb Hemost 7:131-140
28. Dredge K, Hammond E, Davis K, Li C, Liu L, Johnstone K, Handley P, Wimmer N, Gonda T, Gautam A, Ferro V, Bytheway I (2009) The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Invest New Drugs. doi:10.1007/s10637-009-9245-5
29. Duong M, Cockcroft D, Boulet LP, Ahmed T, Iverson H, Atkinson DC, Stahl EG, Watson R, Davis B, Milot J, Gauvreau GM, O'Byrne PM (2008) The effect of IVX-0142, a heparinderived hypersulfated disaccharide, on the allergic airway responses in asthma. Allergy 63: 1195-1201
30. Ernst B, Magnani JL (2009) From carbohydrate leads to glycomimetic drugs. Nat Rev Drug Discov 8:661-677
31. Fernandez C, Hattan CM, Kerns RJ (2006) Semi-synthetic heparin derivatives: Chemical modifications of heparin beyond chain length, sulfate substitution pattern and N-sulfo/N-acetyl groups. Carbohydr Res 341:1253-1265
32. Freeman C, Liu L, Banwell MG, Brown KJ, Bezos A, Ferro V, Parish CR (2005) Use of sulfated linked cyclitols as heparan sulfate mimetics to probe the heparin/heparan sulfate binding specificity of proteins. J Biol Chem 280:8842-8849
33. Freeman I, Kedem A, Cohen S (2008) The effect of sulfation of alginate hydrogels on the specific binding and controlled release of heparin-binding proteins. Biomaterials 29:3260-3268
34. Fritzsche J, Alban S, Ludwig RJ, Rubant S, Boehncke WH, Schumacher G, Bendas G (2006) The influence of various structural parameters of semisynthetic sulfated polysaccharides on the Pselectin inhibitory capacity. Biochem Pharmacol 72:474-485
35. Fugedi P, Peto C (1998) Saccharopeptides and derivatives thereof, Patent No. US 5849709
36. Fugedi P, Tyrrell DJ, Tressler RJ, Stack RJ, Ishihara M (1998) Sulfated maltooligosaccharides with heparin-like properties, Patent No. US 5739115
37. Gandhi NS, Coombe DR, Mancera RL (2008) Platelet endothelial cell adhesion molecule-1 (PECAM-1) and its interactions with glycosaminoglycans I. Molecular modelling studies. Biochemistry 47:4851-4862
38. Guerrini M, Guglieri S, Beccati D, Torri G, Viskov C, Mourier P (2006) Conformational transitions induced in heparin octasaccharides by binding with antithrombin III. Biochem J 399:191-198
39. Gunay NS, Linhardt RJ (1999) Heparinoids: structure, biological activities and therapeutic applications. Planta Med 65:301-306
40. Hara ST, Yoshida KO, Ishihara MI (2007) Use of desulfated heparin, Patent No. EP 1371666/B1
41. Hassan HH (2007) Chemistry and biology of heparin mimetics that bind to fibroblast growth factors. Mini Rev Med Chem 7:1206-1235
42. Henry BL, Connell J, Liang A, Krishnasamy C, Desai UR (2009) Interaction of antithrombin with sulfated, low molecular weight lignins: Opportunities for potent, selective modulation of antithrombin function. J Biol Chem 284:20897-20908
43. Hirsh J, Raschke R (2004) Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:188S-203S
44. Hoarau DQ, Boustta MP, Braud CCLL, Vert MCLL (2007) Amphiphilic heparin derivative formed by coupling a heparin with a bile acid, Patent No. US 2007/0141158 A1
45. Hoffman R, Paper DH, Donaldson J, Alban S, Franz G (1995) Characterisation of a laminarin sulphate which inhibits basic fibroblast growth factor binding and endothelial cell proliferation. J Cell Sci 108(Pt 11):3591-3598
46. Hou S, Sun XL, Dong CM, Chaikof EL (2004) Facile synthesis of chain-end functionalized glycopolymers for site-specific bioconjugation. Bioconjug Chem 15:954-959
47. Islam T, Linhardt R (2003) Chemistry, biochemistry, and pharmaceutical potentials of glycosaminoglycans and related saccharides. In: Wong C (ed) Carbohydrate-based drug discovery. Wiley, Weinheim, pp 407-427
48. Jayakumar R, Nwe N, Tokura S, Tamura H (2007) Sulfated chitin and chitosan as novel biomaterials. Int J Biol Macromol 40:175-181
49. Jayakumar R, Selvamurugan N, Nair SV, Tokura S, Tamura H (2008) Preparative methods of phosphorylated chitin and chitosan - an overview. Int J Biol Macromol 43:221-225
50. Kasbauer CW, Paper DH, Franz G (2001) Sulfated beta-(1- > 4)-galacto-oligosaccharides and their effect on angiogenesis. Carbohydr Res 330:427-430
51. Katsuraya K, Nakashima H, Yamamoto N, Uryu T (1999) Synthesis of sulfated oligosaccharide glycosides having high anti-HIV activity and the relationship between activity and chemical structure. Carbohydr Res 315:234-242
52. Kennedy T (1999) Methods of treating asthma with o-desulfated heparin, Patent No. US 5990097
53. Kennedy T (2009) Methods of treating acute exacerbations of chronic obstructive pulmonary disease, Patent No. US 2009/0054374 A1
54. Kensinger RD, Yowler BC, Benesi AJ, Schengrund CL (2004) Synthesis of novel, multivalent glycodendrimers as ligands for HIV-1 gp120. Bioconjug Chem 15:349-358
55. Khachigian LM, Parish CR (2004) Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies. Cardiovasc Drug Rev 22:1-6
56. Khasraw M, Pavlakis N, McCowatt S, Underhill C, Begbie S, de Souza P, Boyce A, Parnis F, Lim V, Harvie R, Marx G (2009) Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. doi:10.1093/annonc/ mdp524
57. Kim SK, Lee DY, Kim CY, Nam JH, Moon HT, Byun Y (2007) A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study. J Control Release 123:155-163
58. Kong FHD, Ning JHD, Gu JS (2008) Type of oligosaccharides and their sulfate derivatives, Patent No. US 7365191
59. Kumar MN, Muzzarelli RA, Muzzarelli C, Sashiwa H, Domb AJ (2004) Chitosan chemistry and pharmaceutical perspectives. Chem Rev 104:6017-6084
60. Larramendy-Gozalo C, Barret A, Daudigeos E, Mathieu E, Antonangeli L, Riffet C, Petit E, Papy- Garcia D, Barritault D, Brown P, Deslys JP (2007) Comparison of CR36, a new heparan mimetic, and pentosan polysulfate in the treatment of prion diseases. J Gen Virol 88: 1062-1067
61. Lau E, Margolis RU (2009) Inhibitors of slit protein interactions with the heparan sulfate proteoglycan glypican-1: potential agents for the treatment of spinal cord injury. Clin Exp Pharmacol Physiol. doi:10.1111/j.1440-1681.2009. 05318.x
62. Lee E, Pavy M, Young N, Freeman C, Lobigs M (2006) Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Antiviral Res 69:31-38
63. Lee JH, Canny MD, De Erkenez A, Krilleke D, Ng YS, Shima DT, Pardi A, Jucker F (2005) A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci USA 102:18902-18907
64. Liu C-J, Lee P-H, Lin D-Y, Wu C-C, Jeng L-B, Lin P-W, Mok K-T, Lee W-C, Yeh H-Z, Ho M-C, Yang S-S, Lee C-C, Yu M-C, Hu R-H, Peng C-Y, Lai K-L, Chang SS-C, Chen P-J (2009) Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage. J Hepatol 50:958-968
65. Livaoglu M, Kerimoglu S, Sonmez B, Livaoglu A, Karacal N (2009) The effect of Hirudoid on random skin-flap survival in rats. J Plast Reconstr Aesthet Surg. doi:10.1016/j.bjps.2009.03.018
66. Logeart-Avramoglou D, Jozefonvicz J (1999) Carboxymethyl benzylamide sulfonate dextrans (CMDBS), a family of biospecific polymers endowed with numerous biological properties: A review. J Biomed Mater Res 48:578-590
67. MacLaren R, Stringer KA (2007) Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory syndrome. Pharmacotherapy 27:860-873
68. Magnani JL (2004) The discovery, biology, and drug development of sialyl Lea and sialyl Lex. Arch Biochem Biophys 426:122-131
69. Magnani JL, Woodlark R, Butcher EC, Berg EL (2000) Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules, Patent No. US 6121233
70. Magnani JLTCRGMD (2009) Pan-selectin inhibitor with enhanced pharmacokinetic activity, Patent No. WO 2009/126556 A1
71. Martin DJ, Toce JA, Anevski PJ, Tollefsen DM, Abendschein DR (1999) Anticoagulant and antithrombotic activity of maltodapoh, a novel sulfated tetrasaccharide. J Pharmacol Exp Ther 288:516-521
72. Maynard HD, Hubbell JA (2005) Discovery of a sulfated tetrapeptide that binds to vascular endothelial growth factor . Acta Biomater 1:451-459
73. Monien BH, Desai UR (2005) Antithrombin activation by nonsulfated, non-polysaccharide organic polymer. J Med Chem 48:1269-1273
74. Mousa SA, Feng X, Xie J, Du Y, Hua Y, He H, O'Connor L, Linhardt RJ (2006) Synthetic oligosaccharide stimulates and stabilizes angiogenesis: structure-function relationships and potential mechanisms. J Cardiovasc Pharmacol 48:6-13
75. Myskiw C, Deschambault Y, Jefferies K, He R, Cao J (2007) Aurintricarboxylic acid inhibits the early stage of vaccinia virus replication by targeting both cellular and viral factors. J Virol 81:3027-3032
76. Nair VG, Joseph JP, Bernstein S (1977) Complement inhibitors, Patent No. US 4021544
77. Nair VG, Joseph JP, Bernstein S (1978) Polygalactosido-sucrose Poly(H-)sulfate salts, Patent No. US 4098995
78. Nimjee SM, Oney S, Volovyk Z, Bompiani KM, Long SB, Hoffman M, Sullenger BA (2009) Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. RNA 15:2105-2111
79. Nunn A, McCormack S, Crook AM, Pool R, Rutterford C, Hayes R (2009) Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention. Trials 10:99
80. O'Loughlin J, Millwood IY, McDonald HM, Price CF, Kaldor JM, Paull JR (2009) Safety, tolerability, and pharmacokinetics of SPL7013 Gel (VivaGel(R)): A dose ranging, phase I study. Sex Transm Dis. doi:10.1097/OLQ.0b013e3181bc0aac
81. Oreste PM, Zoppetti GM (2005) Anticoagulant and antithrombotic LMW-glycosaminoglycans derived from K5 polysaccharide and process for their preparation, Patent No. US 2005/ 0027117 A1
82. Pahi V, Ferrer J, Verbruggen A, Milano V, Roura R, Verson A (2005) New therapeutic use for a group of sulphated polysaccharides, Patent No. WO 2005/084610 A3R4
83. Papoulias UE, Wyld PJ, Haas S, Stemberger A, Jeske W, Hoppensteadt D, Kammereit A (1993) Phase I - study with aprosulate, a new synthetic anticoagulant . Thromb Res 72:99-108
84. Papy-Garcia D, Barbier-Chassefière V, Rouet V, Kerros M-E, Klochendler C, Tournaire M-C, Barritault D, Caruelle JP, Petit E (2005) Nondegradative sulfation of polysaccharides. Synthesis and structure characterization of biologically active heparan sulfate mimetics. Macromolecules 38:4647-4654
85. Parish CR, Cowden WB (2000) Preparation and use of sulfated oligosaccharides, Patent No. US 6143730
86. Parsons CL (1997) Epithelial coating techniques in the treatment of interstitial cystitis. Urology 49:100-104
87. Petitou M, Nancy-Portebois V, Dubreucq G, Motte V, Meuleman D, de Kort M, van Boeckel CA, Vogel GM, Wisse JA (2009) From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile. Thromb Haemost 102:804-810
88. Ponedel'kina I, Odinokov V, Lukina E, Tyumkina T, Khalilov L, Dzhemilev U (2006) Chemical modification of heparin. Russ J Bioorg Chem 32:472-477
89. Presta M, Oreste P, Zoppetti G, Belleri M, Tanghetti E, Leali D, Urbinati C, Bugatti A, Ronca R, Nicoli S, Moroni E, Stabile H, Camozzi M, Hernandez GA, Mitola S, Dell'Era P, Rusnati M, Ribatti D (2005) Antiangiogenic activity of semisynthetic biotechnological heparins: lowmolecular- weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists. Arterioscler Thromb Vasc Biol 25:71-76
90. Raake W, Klauser RJ, Elling H, Zeiller P, Meinetsberger E (1994) Derivatives of bis-aldonic acid amides and their anticoagulant and antithrombotic properties. Semin Thromb Hemost 20: 176-181
91. Raghuraman A, Riaz M, Hindle M, Desai UR (2007) Rapid and efficient microwave-assisted synthesis of highly sulfated organic scaffolds. Tetrahedron Lett 48:6754-6758
92. Raman R, Venkataraman G, Ernst S, Sasisekharan V, Sasisekharan R (2003) Structural specificity of heparin binding in the fibroblast growth factor family of proteins. Proc Natl Acad Sci USA 100:2357-2362
93. Rele SM, Iyer SS, Baskaran S, Chaikof EL (2004) Design and synthesis of dimeric heparinoid mimetics. J Org Chem 69:9159-9170
94. Renner C, Piehler J, Schrader T (2006) Arginine- and lysine-specific polymers for protein recognition and immobilization. J Am Chem Soc 128:620-628
95. Rose MJ, Page C (2004) Glycosaminoglycans and the regulation of allergic inflammation. Curr Drug Targets Inflamm Allergy 3:221-225
96. Rouet V, Meddahi-Pelle A, Miao HQ, Vlodavsky I, Caruelle JP, Barritault D (2006) Heparin-like synthetic polymers, named RGTAs, mimic biological effects of heparin in vitro. J Biomed Mater Res A 78:792-797
97. Shoji T, Ikushima N, Kaname Katsuraya S, Nahoko Takahashi C, Fusayo Kobayashi S, Toshiyuki Uryu T, Takashi Yoshida T, Naoki Yamamoto T, Hideki Nakashima T (1994) Sulfated tocopheryl oligosaccharides and antiviral agents including the same as active ingredients, Patent No. US 5280111
98. Smelcerovic A, Knezevic-Jugovic Z, Petronijevic Z (2008) Microbial polysaccharides and their derivatives as current and prospective pharmaceuticals. Curr Pharm Des 14:3168-3195
99. Suzuki A, Toyoda H, Toida T, Imanari T (2001) Preparation and inhibitory activity on hyaluronidase of fully O-sulfated hyaluro-oligosaccharides. Glycobiology 11:57-64
100. Ueki M, Watanabe S, Ishii Y, Okunaka O, Uchino K, Saitoh T, Higashi K, Nakashima H, Yamamoto N, Ogawara H (2001) Synthesis and anti-HIV activity of nonatyrosine N- and O1-9-decasulfate. Bioorg Med Chem 9:477-486
101. Urbinati C, Chiodelli P, Rusnati M (2008) Polyanionic drugs and viral oncogenesis: A novel approach to control infection, tumor-associated inflammation and angiogenesis. Molecules 13:2758-2785
102. Usher TC, Patel N, Tele CG (1995) Process for preparing soluble alkali metal salts of cellulose sulfate using chlorosulfuric acid and pyridine, Patent No. US 5378828
103. Vecchio C, Frisinghelli A (2008) Topically applied heparins for the treatment of vascular disorders: A comprehensive review. Clin Drug Investig 28:603-614
104. Vogel G (2006) Pulmonary administration of an antithrombotic compound, Patent No. WO 2006/ 037771 A1
105. Wall D, Douglas S, Ferro V, Cowden W, Parish C (2001) Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides. Thromb Res 103: 325-335
106. Wang X, Zhang L (2009) Physicochemical properties and antitumor activities for sulfated derivatives of lentinan. Carbohydr Res 344:2209-2216
107. Wessel H (1997) Heparinoid mimetics, vol 187, Topics in current chemistry. Springer, Heidelberg, pp 215-239
108. Wessel HP, Chucholowski A, Fingerle J, Iberg N, M€arki HP, M€uller R, Pech M, Pfister-Downar M, Rouge M, Schmid G, Tschopp T (2005) From glycosaminoglycans to heparinoid mimetics with antiproliferative activity. In: Yves C (ed) Carbohydrate mimics. Wiley, Weinheim, pp 417-431
109. Yang DW, Ohta Y, Yamaguchi S, Tsukada Y, Haraguchi Y, Hoshino H, Amagai H, Kobayashi I (1996) Sulfated colominic acid: An antiviral agent that inhibits the human immunodeficiency virus type 1 in vitro. Antiviral Res 31:95-104
110. Zhao H, Liu H, Chen Y, Xin X, Li J, Hou Y, Zhang Z, Zhang X, Xie C, Geng M, Ding J (2006) Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis. Cancer Res 66:8779-8787